MindBio Therapeutics (XCNQ:MBIO) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

MindBio Therapeutics's Capital Expenditure for the three months ended in Mar. 2024 was C$0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was C$0.15 Mil.

Hence, MindBio Therapeutics's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.00.

MindBio Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for MindBio Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Capex-to-Operating-Income Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Capex-to-Operating-Income

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Operating-Income	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of MindBio Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, MindBio Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Capex-to-Operating-Income falls into.

MindBio Therapeutics Capex-to-Operating-Income Calculation

MindBio Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-2.822
	=	N/A

MindBio Therapeutics's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	0.154
	=	0.00

MindBio Therapeutics (XCNQ:MBIO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

MindBio Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.